POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
04 sept. 2022 18h10 HE
|
POINT Biopharma
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
01 sept. 2022 16h15 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that...
Shattuck Labs Announces Participation in Upcoming September Conferences
01 sept. 2022 16h15 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
01 sept. 2022 16h05 HE
|
Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
The AJMC Institute for Value-Based Medicine Hosts “Closing the Access Gap: Ensuring Innovation Saves Lives” Event in Orange County, CA
01 sept. 2022 09h30 HE
|
The American Journal of Managed Care®
CRANBURY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, today announced...
Persbericht Biocartis Group NV: Biocartis start commercialisatie in Europa van SkylineDx’s innovatieve Merlin™ Assay (CE-IVD) voor melanoma patiënten
01 sept. 2022 01h01 HE
|
Biocartis NV
PERSBERICHT: 1 september 2022, 07:01 CEST Biocartis start commercialisatie in Europa van SkylineDx’s innovatieve Merlin™ Assay (CE-IVD) voor melanoma patiëntenMerlin helpt melanoompatiënten te...
Press release Biocartis Group NV: Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients
01 sept. 2022 01h01 HE
|
Biocartis NV
PRESS RELEASE: 1 September 2022, 07:01 CEST Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma PatientsMerlin helps identify melanoma...
Persbericht Biocartis Group NV: Biocartis kondigt aan alomvattende herkapitalisatie maatregelen aan te gaan om haar kaspositie te versterken en groei te ondersteunen
01 sept. 2022 01h00 HE
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE/VOORWETENSCHAP 1 september 2022, 07:00 CEST Biocartis kondigt aan alomvattende herkapitalisatie maatregelen aan te gaan om haar kaspositie te versterken en...
Press release Biocartis Group NV: Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and Support Growth
01 sept. 2022 01h00 HE
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION/INSIDE INFORMATION 1 September 2022, 07:00 CEST Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and...
Revolution Medicines to Participate in Upcoming Investor Conferences
31 août 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...